Ignite Creation Date:
2024-05-05 @ 9:42 PM
Last Modification Date:
2024-10-26 @ 10:08 AM
Study NCT ID:
NCT00943267
Status:
COMPLETED
Last Update Posted:
2011-03-16
First Post:
2009-07-21
Brief Title:
Effect of Intrapulmonary Recombinant Human Activated Protein C APC on Coagulation and Inflammation After Lipopolysaccharide LPS
Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Organization:
Academisch Medisch Centrum - Universiteit van Amsterdam AMC-UvA
Study Overview
Official Title:
Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Recombinant human Activated Protein C rhAPC has been shown to reduce the mortality of patients with severe sepsis The biological effects of APC are pleiotropic and can be roughly divided in anticoagulant and cytoprotective effects Lung infection and inflammation are associated with reduced bronchoalveolar levels of endogenous APC Recent evidence derived from animal studies indicates that local administration of rAPC into the lungs exerts local anti-inflammatory and anticoagulant effects In this study we propose to study the potential of locally administered APC within a lung subsegment to inhibit lipopolysaccharide LPS induced lung inflammation and coagulation in humans
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MEC 08188 | None | None | None |